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Abstract 
Background: Understanding cardiac mechanics is important for developing cardiac therapies. Current modalities 
for assessing cardiac mechanics sample patient’s heart at specific heart rate, contractility, preload, and afterload. The 
objective of this study was to test the feasibility of a novel system composed of intra-cardiac leads equipped with an 
inertial module chip (3D accelerometers and 3D gyroscopes) in monitoring continuous heart motion.
Methods: In this descriptive study, four healthy pigs were anesthetized and instrumented with motion-sensitive 
intra-cardiac leads; the temporal correlation between signals from motion sensors and tissue Doppler from the chest 
wall were studied; changes in real-time heart accelerations (ACC) and angular velocity (ANGV) were reported as per-
centages of change from baseline.
Results: Heart motion signals were sensed continuously from the right ventricular apex (RVa) and coronary sinus 
(CS). Volume expansion did not produce significant changes in the ACC and ANGV signals. Increasing heart rate 
increased the peak systolic ACC signal recorded from RVa and CS by 94 and 76%, respectively, and increased both 
peak systolic (61% RVa and 27% CS) and diastolic ANGV (200% CS vs. 31% RVa). Epinephrine administration increased 
peak systolic ACC signals at both sites (246% RVa; 331% CS). Peak systolic and diastolic ANGV increased in response to 
epinephrine (systolic: 198% RVa and 175% CS; diastolic: 723% CS and 89% RVa) (p = 0.125 for all changes expressed 
in percent). Temporal correlation between the ANGV signal and tissue Doppler signal was detected throughout all 
interventions.
Conclusions: A novel system for continuously monitoring heart motion signals from within the heart was presented. 
Heart motion signals in response to physiologic manipulations were characterized.
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Background
Understanding cardiac mechanics is crucial for plan-
ning novel therapeutic devices. Unfolding the mechanics 
of the heart is an ongoing process, with new technolo-
gies providing important insights [1]. Pressure–volume 
measurement provides the corresponding data loops that 
describe the external work of the left ventricle (LV) and 
unique properties of the heart and circulation at distinct 
systolic and diastolic times [2]. However, such measure-
ments do not provide information on the three-dimen-
sional (3D) twisting–untwisting motion of the heart. 
Echocardiography demonstrates cardiac motion, as does 
cardiac MRI, which is highly informative but is resource 
intensive. The main limitations of echocardiography are 
due to the fact that the complex 3D motion of the heart is 
interpreted based on 2D images, and that cropped images 
are related to a specific clinical condition regarding heart 
rate (HR), blood pressure, blood volume, and medica-
tions. Newer techniques such as high-resolution echocar-
diography [3, 4], magnetic resonance myocardial tagging 
[5], speckle tracking echocardiography [6], and diffusion 
tensor MRI [7] were introduced to provide data regard-
ing the unique 3D, twisting–untwisting motion of the 
heart. Yet, all these techniques sample heart motion dur-
ing specific hemodynamic conditions. Peak endocardial 
acceleration (PEA) is a proprietary, accelerometer-based 
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technology developed by Sorin (Sorin CRM SAS, Salug-
gia, Italy) which continuously measures myocardial con-
tractility [8]. Yet, this technology was not reported to 
monitor heart motion throughout the cardiac cycle.
We hypothesized that a novel system of leads that 
continuously monitors heart motion from inside the 
heart will provide valuable physiologic information that 
is unattainable with current methods. In this work, we 
describe the feasibility of our technology in measur-
ing continuous heart motion signals in a healthy por-
cine model. The complex beat-to-beat real-time cardiac 
motion is described as viewed from the right ventricular 
apex (RVa) and coronary sinus (CS), and is correlated 
with standard tissue Doppler (tD) signals.
Methods
Motion sensors and leads
The motion of cardiac walls was assessed by motion sen-
sors (a single-chip inertial module composed of a 3D 
accelerometer and 3D gyroscope type LSM330D by ST 
microelectronics Ltd., Fig.  1, right lower corner). The 
sensor was glued to the distal end (Fig.  1, right upper 
corner, A) of a standard active fixation intra-cardiac lead 
(model Flextend 4088, Boston Scientific). At the tip of 
the distal end of the lead is an extendable/retractable spi-
ral (A) for anchoring the lead to myocardial tissue. Sen-
sor dimensions are 5.5 ×  3.0 ×  1.0  mm. The spiral can 
be controlled from the proximal end of the intra-cardiac 
lead (Fig. 1b). Conductors, coated with a thin Teflon tape 
that attaches them to the outer surface of the lead, con-
nect the sensor with an evaluation board (Fig. 1c). Digital 
signals were transferred from the sensor to the evaluation 
board and to the software managing data acquisition and 
real-time analysis (Labview, National Instruments, Aus-
tin, Texas). Similarly, a CS lead (Deflectable decapolar 
catheter, Dynamic XT Bard, Lowell, MA) was prepared 
and used. Signals were recorded from both RVa and CS, 
as the former lead represents motion of the apex and the 
latter motion of cardiac base and atria.
Animal preparation
The study was approved by the Institutional Animal 
Research committee at the Technion and all experimen-
tal procedures were performed in accordance with the 
guidelines for the utilization and care of animals used in 
research. Domestic pigs weighing 56–62  kg were anes-
thetized with isoflurane (2%), intubated and mechanically 
ventilated using room air. We studied 11 pigs. In the first 
pigs (n = 7), we established the experimental model and 
tested the sensing and recording systems. In four pigs, 
the full system was tested using the same protocol. We 
report the results for these four pigs.
After anesthesia, 16-Fr introducers were inserted into 
the right and left jugular veins and intra-cardiac leads 
tipped with 3D accelerometers and gyroscopes were 
positioned in the RVa and CS. Pigtail catheters were 
inserted through the femoral arteries into the apex of the 
LV and ascending aorta, for continuous measurement of 
pressures at these sites. A pacing lead was introduced 
from the right femoral vein into the right atrium (ERA 
3000, pacing system, Biotronik, Berlin, Germany). Stand-
ard limb ECG was recorded throughout the study. Urine 
output was monitored using a urinary catheter. Figure 2 
shows a fluoroscopic image (OEC 9800 PLUS Mobile 
Fig. 1 Sensor assembled on intra-cardiac lead. Bare motion sensor 
(right lower corner) and assembled sensor coated by Teflon tape on 
distal end of intra-cardiac lead (right upper corner). A helix at tip of 
lead; B proximal end of lead; C connector
Fig. 2 A fluoroscopic image of an instrumented animal. A pigtail 
catheter positioned in the apex of LV for measuring LV pressure; 
B pigtail catheter for measuring aortic pressure positioned in the 
ascending aorta; C two 16-Fr introducers; D screwing intra-cardiac 
lead positioned in RV apex; E standard intra-cardiac lead positioned in 
CS; motion sensors are assembled on tips of both intra-cardiac leads 
(not visible); F standard pacing lead positioned in RA. This lead was 
inserted from a femoral vein
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C-arm, by GE Healthcare, USA) of the catheters and 
leads within the heart.
Transthoracic echocardiography
All echocardiographic examinations were performed 
using a Vivid i machine (GE Healthcare, USA). A com-
plete comprehensive transthoracic echocardiographic 
and Doppler screening examination was performed to 
verify normal structure and function of the heart. Dur-
ing the study, we recorded tD images simultaneous with 
heart motion and hemodynamic signals.
Operating system
Control of sensors, data acquisition, and real-time set-
tings (related to the process of data acquisition) were 
obtained using a PC that controlled a DAQ board (NI 
60211, National Instruments, Texas, USA). Signals were 
stored and analysis was performed off-line. A mutual 
time-line was documented for all devices and signals.
Experimental protocol
After the animals were prepared and instrumented, three 
interventions were performed to characterize motion 
signals of the heart. Baseline measurements were deter-
mined. Then, the effect of rapid volume loading was stud-
ied by administering 1  L of normal saline 0.9% through 
the left jugular introducer within 10  min. The second 
intervention investigated the effect of different heart rates 
using RA pacing at an initial rate of 10  bpm above the 
animals’ baseline intrinsic HR. Pulse width was 1–1.5 ms 
and peak amplitude 6–8  V. Pulse width and amplitude 
were set so as to securely induce pacing. The pacing rate 
was increased by 10 bpm every 2 min to a maximal HR of 
130 bpm.
Third, the effects of epinephrine on both contractility 
and heart rate were studied by intravenously administer-
ing boluses of 0.01, 0.015, and 0.02  mg of epinephrine. 
Second and third boluses of epinephrine were admin-
istered after HR resumed the pre-injection rate. Ten-
minute intervention-free intervals separated consecutive 
interventions. Reference hemodynamic, echocardio-
graphic and cardiac motion signals were simultaneously 
recorded during interventions.
Off‑line analysis of motion signals
All signals were stored in a format accessible by MATLAB 
(The Mathworks, Massachusetts, USA). Analysis was 
performed using proprietary software. Heart motion sig-
nals (3 axes of ACC and 3 axes of ANGV from 2 sensors) 
were recorded separately. The composite signals pre-
sented throughout this work are Ci =
√(
X
2
i
+ Y 2
i
+ Z2
i
)
 
where C denotes the magnitude of the composite signal 
of X, Y, and Z, which are the signals recorded in each of 
the axes, and i denotes the time index. Ci represents ACC 
or ANGV. Recording Ci was defined as a sufficient goal, 
providing the magnitude of rotation in each of the twist–
untwist directions. Recording and considering each of 
the axes of the ACC and ANGV signals would lead to 
dependence on the exact location and positioning of the 
lead. A change in the latter may result in a change in the 
signal. But calculating the composite lead, Ci, overcomes 
this variability.
Statistics
This study was a proof of concept and a feasibility study. 
To present trends of interventions, we calculated the 
mean (±STD) of baseline and last measurements for all 
animals in each of the interventions. Differences between 
mean baseline values (before intervention) and mean 
final measurement values (end of intervention) are pre-
sented in absolute and percent values. To test for signifi-
cance of differences, we applied the Wilcoxon sign rank 
test. For all analyses performed, a p value <0.05 was con-
sidered statistically significant.
Results
Description of composite real‑time heart accelerations 
(ACC) and angular velocities (ANGV)
Standard hemodynamic and heart motion signals were 
recorded simultaneously and showed normal physiology 
for the four animals: after the QRS complex, LV pres-
sure increased to the point where the aortic valve opened 
and LV and aortic pressures equilibrated (Fig.  3, upper 
panel). Approximately at the end of the T wave, the ejec-
tion phase terminated, the aortic valve closed, and LV 
and aortic pressures resumed their diastolic level. The 
composite systolic ACC signal (Fig. 3, middle panel, dot-
ted ellipse), which we termed systolic tension onset sig-
nal (STOS), initiated with the QRS and persisted with 
LV pressure rise. STOS duration was ~100  ms. Peak-to-
peak amplitude (maximal to minimal value) of STOS was 
repeatedly greater than that of the ACC signal preceding 
and following it. The composite ANGV signal also started 
with the QRS (Fig. 3, lower panel, dotted box) and typi-
cally lasted longer than STOS (~150  ms). We note that 
only the composite amplitudes (not the directions) of the 
ACC and ANGV are presented in the graph. With the 
termination of the T wave and the onset of LV pressure 
decline, the composite ACC and ANGV signals of diastole 
were detected (Fig.  3, middle and lower panels, dashed 
ellipse and box, respectively). The duration of the diastolic 
ANGV signal was greater than that of the ACC signal, 
and this component terminated before the P wave (Fig. 3, 
arrow). We emphasize that LA motion is clearly sensed by 
CS and RVa sensors. This invaluable information of the 
mechanical activity of the atria is not available from ECG.
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Effect of rapid volume administration
All four animals were administered normal saline as 
described in the “Methods”. Peak-to-peak STOS and peak 
systolic and diastolic ANGV signals were not affected by 
rapid volume expansion (data are not shown).
Effect of pacing (increasing heart rate)
Peak-to-peak STOS and peak systolic and diastolic 
ANGV signals increased in response to increasing heart 
rate (pacing). Increasing heart rate with pacing increased 
peak-to-peak STOS recorded from RVa and CS by 94 and 
76%, respectively (p = 0.125) (Fig. 4, upper panels). Pac-
ing increased both peak systolic and diastolic ANGV. The 
effect of increasing heart rate on peak systolic ANGV 
recorded from RVa was greater than that recorded 
from CS (61 vs. 27%; p =  0.125; Fig.  4, middle panels). 
Peak diastolic ANGV recorded from RVa increased to 
a maximum and then decreased for all four animals (in 
one animal maximal diastolic ANGV reached 110  beat/
min, in two animals 120 beat/min, and in the fourth ani-
mal 130 beat/min). The diastolic ANGV signals recorded 
from CS showed a similar phenomenon for three animals 
(Nos. 8, 10, 11); while for one animal (No. 9) the signal 
increased with increasing heart rate (RA pacing), and 
did not reach a maximum. The effect of pacing on peak 
diastolic ANGV was greater at CS than at RVa (200 vs. 
31%; Fig.  4, lower panels). The peak-to-peak STOS and 
the peak systolic and diastolic ANGV to higher heart 
rates were weaker in two animals (Nos. 8, 9) than that for 
the other two animals (Nos. 10, 11). Table 1, left column, 
summarizes the effects of pacing on STOS, and peak sys-
tolic and diastolic ANGV signals.
Effect of epinephrine
All heart motion signals increased in response to epi-
nephrine administration (Fig.  5). Peak-to-peak STOS 
recorded from RVa increased by 246% whereas that 
recorded at CS increased by 331% (p  =  0.125). Impor-
tantly, the most prominent increases in peak-to-peak 
STOS recorded from RVa and CS were observed after 
the first dose of epinephrine (0.01 mg). Further increases 
in heart motion were relatively smaller. Peak-to-peak 
STOS recorded from CS leveled to a plateau at epineph-
rine boluses greater than 0.015 mg. Peak systolic ANGV 
recorded from RVa and CS increased in response to epi-
nephrine administration (198 and 175%, respectively; 
Fig. 3 Hemodynamic, composite ACC and ANGV signals recorded from a sensor (animal 10, RVa). ECG, LV and aortic pressures are displayed in 
the upper panel. The vertical line crossing all three panels is aligned with the R wave of the second ECG complex. The middle panel displays the 
composite systolic and diastolic ACC signals (dotted and dashed ellipses, respectively). The lower panel displays the composite systolic and diastolic 
ANGV signals (dotted and dashed boxes, respectively). Filters were not used when data were recorded to avoid phase delays. Vertical arrow points to 
the second P wave. Acc accelerometer, deg degrees, g kg m/s2, Gyro gyroscopic signal measuring ANGV, mmHg millimeters of mercury, PAO aortic 
pressure, PLV LV pressure, sec second, Tot total or composite signal
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Fig. 4 Effect of pacing. Left and right columns provide graphs recorded from RVa and CS, respectively. Row 1 displays peak-to-peak STOS as a func-
tion of pacing. Rows 2 and 3 display peak systolic and diastolic ANGV as a function of pacing, respectively. Each point on the graph represents a 
value obtained by averaging 100 consecutive values. The first icon for each animal represents the baseline value prior to pacing
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p  =  0.125). The effect of epinephrine administration 
on peak diastolic ANGV at CS was greater than that 
recorded from RVa (723 vs. 89%, respectively; p = 0.125).
Variability in the intensity of motion was observed 
between animals and between sites of measurement. 
When heart motion signals were highly intensified in 
response to epinephrine as recorded from RVa, the sig-
nals recorded from CS were of lower magnitude, and 
vice versa. Two animals (Nos. 9, 11) exhibited a greater 
peak-to-peak STOS response to epinephrine as recorded 
from RVa (compared to animals Nos. 8, 10), whereas 
the opposite response was discerned from the CS lead 
(Fig. 5, upper panels). Peak systolic and diastolic ANGV 
responded in a similar fashion; two animals (Nos. 10, 
11) exhibited a greater peak systolic and diastolic ANGV 
response as recorded from CS (compared to animals Nos. 
8, 9). Trends detected during epinephrine intervention 
are summarized in Table 1, right column.
Temporal correlation between the ANGV signal and the 
standard tissue Doppler signal
The STOS (acceleration) and ANGV signals are novel and 
their full significance is yet to be investigated. However, 
during all studies in all animals, the temporal correlation 
between these motion signals and the standard tD signal 
recorded from the animal body surface was preserved. 
Specifically, ANGV signals during systole occurred at 
the same time as the s′ tD signal. During diastole, ANGV 
components occurred with e′, and a′ tD signal (Fig.  6). 
Though ANGV signals varied in shape between animals, 
the temporal correlation between the ANGV signal and 
tD persisted for all four animals.
Discussion
The goal of this study was to test, on a healthy porcine 
model, the feasibility of a novel system for continuously 
measuring heart motion signals. The motion signals, 
ACC and ANGV, recorded from sensors, were repro-
ducible throughout heart cycles and three physiologic 
manipulations. STOS reflects systolic wall tension build 
up in the cardiac muscle, whereas ANGV reflects systolic 
and diastolic velocities of twisting–untwisting motions, 
respectively. A signal similar to STOS, PEA, was pre-
sented by Sorin (Sorin CRM SAS, Saluggia, Italy) [8] and 
was used for weekly optimization of a cardiac resynchro-
nization therapy (CRT) system. PEA provides continu-
ous measurement of cardiac contractility, but it was not 
reported to monitor the twist–untwist motion of the 
heart. Hyler et  al. [9] and Grymyr et  al. [10] reported 
their experience with epicardial 3D accelerometer as a 
tool for detecting LV function in the experimental setting 
of post-cardiac surgery care.
ANGV signals are obtained from speckle tracking 
echocardiography and MRI [3–7]. However, the lat-
ter systems provide “snap-shot images” of the signals, 
whereas the system presented in the current study 
provides continuous data. Since cardiac twisting and 
untwisting motions must be equal in order to maintain 
the heart at the same position in the chest, time integrals 
of systolic and diastolic ANGV are also expected to be 
equal. These calculations were not performed as only two 
locations in the heart were studied, and these two sites 
may not necessarily record all cardiac rotational motion. 
ANGV may change in response to manipulations at car-
diac sites that are not monitored.
Rapid volume loading (administration of 100 ml saline 
per minute for 10 min) did not produce STOS and ANGV 
signals that were different from baseline; therefore, con-
clusions may not be drawn. The volume overloading 
protocol that we used was insufficient to induce a signifi-
cant STOS and ANGV response [11]. Hyler et al. rapidly 
infused 500 ml of a colloid fluid to produce an increase 
in tissue velocity from 14.1 to 14.8  cm/s (p  <  0.05) [9]. 
Grymyr et  al. used a bolus of 500  ml Ringer acetate to 
increase preload, yet their velocity signal (derived from 
the accelerometer) showed an increase in velocity at the 
basal area of the LV, where in contrast velocity decreased 
in both the basal area of the RV and LV apex [10].
Table 1 Descriptive analysis of the trends observed during pacing and epinephrine interventions
CS coronary sinus, DAV diastolic angular velocity, RVa right ventricle apex, SAV systolic angular velocity, STOS systolic tension onset signal
Pacing Epinephrine
Baseline Last measurement Diff Diff% Baseline Last measurement Diff Diff%
STOS-RVa 0.53 ± 0.08 1.02 ± 0.18 0.49 ± 0.15 94.5 ± 28.3 0.42 ± 0.1 1.43 ± 0.34 1.02 ± 0.27 246.04 ± 40.8
STOS-CS 0.43 ± 0.22 0.71 ± 0.25 0.28 ± 0.12 76.8 ± 46.0 0.35 ± 0.13 1.46 ± 0.35 1.11 ± 0.27 331.7 ± 90.8
Peak SAV-RVa 140.93 ± 20.4 220.4 ± 51.9 79.5 ± 62.6 60.9 ± 56.4 117.7 ± 21.2 343.1 ± 52.9 225.4 ± 58.9 198.4 ± 68.8
Peak SAV- CS 147.23 ± 59.4 190.1 ± 98.5 42.9 ± 48.2 26.9 ± 22.2 132.9 ± 69.0 317.7 ± 140.2 184.7 ± 86.0 174.8 ± 132.0
Peak DAV-RVa 147.2 ± 61.6 191.2 ± 76.3 44.1 ± 25.7 30.8 ± 12.5 138.4 ± 45.5 252.5 ± 89.7 114.1 ± 73.5 89.4 ± 59.6
Peak DAV- CS 59.8 ± 3.9 181.1 ± 56.3 121.3 ± 53.6 200.2 ± 81.4 36.7 ± 7.9 333.9 ± 293.0 297.3 ± 285.7 729.9 ± 605.3
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Fig. 5 Effect of epinephrine. Left and right columns provide graphs recorded from RVa and CS, respectively. Row 1 displays peak-to-peak STOS as a 
function of epinephrine dose. Rows 2 and 3 display peak systolic and diastolic ANGV as a function of epinephrine dose, respectively. Every point in 
the figure represents the mean ± standard deviation of 21 points around peak epinephrine effect
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During pacing, STOS and ANGV signals recorded from 
the RVa were on average greater than those recorded 
from the CS. This finding is hypothesized to be related 
to three observations: (1) the twisting trajectory taken 
by the RVa sensor (positioned on a lead near the cardiac 
apex) is larger than that by the CS sensor (positioned 
near the cardiac base). Previous studies showed that the 
rotation of the apex of the heart is greater than that of the 
cardiac base [1]. (2) The leverage effect on the RVa sensor 
is greater than that operating on the CS sensor, because 
the distance between the RVa sensor and an imaginary 
point between the aorta and the pulmonary artery (the 
great vessels anchoring the heart) is greater than the dis-
tance between the CS sensor and the latter anchoring 
point. (3) The lead and sensor positioned in the CS are 
limited by the anatomy of the vein, restricting their free 
motion. It is acknowledged that the size of the sensor 
attached to the lead currently limits positioning the lead 
more distally.
During epinephrine administration both the RVa and 
CS sensors responded similarly. The initial epinephrine 
bolus of 0.01 mg produced a prominent effect on STOS 
and ANGV, and subsequent higher doses had smaller 
incremental effects. The boluses of epinephrine used in 
this study forced the cardiac apex (RVa) and base (CS) 
to reach their maximum ability to rotate. These observa-
tions demonstrate that our system has the potential of 
assessing the maximal effect of an intervention on heart 
motion. This effect can be detected from the “Starling-
like” curves such as shown in Figs. 4 and 5. This may be 
relevant for assessing the effects of inotropic and chrono-
tropic medications, especially in the situation in which a 
drug is added to an existing regimen. Hyler et al. [9] and 
Grymyr et al. [10] report similar responses of the epicar-
dial accelerometer to catecholamine administration.
This study also shows that systolic twisting and dias-
tolic untwisting, as reflected by ANGV, may occur mainly 
by the apex or by the base. Our system is able to distin-
guish between a mainly apical or basal twist–untwist 
response to epinephrine.
In this work, the temporal correlation between the 
ANGV signals and the standard tD echocardiography 
Fig. 6 Temporal correlation between ANGV signal and tissue Doppler signal. Hemodynamic signals (ECG, LV and aortic pressures, upper panel), 
ANGV signal (middle panel) and tissue Doppler signal (lower panel) are displayed. Five vertical lines cross the three panels. Starting from left, the first 
line displays the onset of the ECG. The systole is confined between the first and second lines. In the lower panel the s′ signal is observed correlating 
with the systolic ANGV signal (middle panel). Between the second and third lines, the early rapid filling phase of diastole is observed (LV pressure 
decreases, upper panel). The correlating ANGV signal is prominent (middle panel) whereas the e′ signal (tD, lower panel) peaks in the second half of 
this period. Between the third and fourth lines the short diastasis can be detected, where LV pressure is almost constant, ANGV is minimal, and the 
Doppler signal records no tissue motion. At this period, the P wave may be observed. Between the fourth and fifth lines, the ANGV signal represents 
a rotation motion that correlates with the a′ signal (tD, lower panel)
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was demonstrated. This correlation is predicted as both 
modalities sense myocardial tissue motion.
The novel system presented describes systolic and 
diastolic heart motion signals which reflect mechani-
cal events of the heart cycle. As one of the goals of car-
diac resynchronization therapy (CRT) is to optimize 
the mechanical synchronization between LA and LV, a 
mechanical event (not an electric event), i.e. ANGV sig-
nal, is proposed to be more appropriate for this purpose. 
Presently, the event of optimal LA emptying as the ideal 
timing for LV stimulation is determined using two com-
ponents: (a) P wave detection and (b) a preset fixed time 
interval from the P wave [12]. Several factors such as nor-
mal physiologic variability and arrhythmias can lead to 
changes in the time from P wave detection to optimal LA 
emptying. Chung et al. have shown that the duration of 
the transmitral atrial flow velocity wave, A wave, shortens 
by 16 per 100% increase in HR in healthy young subjects 
[13]. Therefore, the method that is currently available 
may be inadequate as it cannot adjust the preset fixed 
time interval to these changes. Instead of relying on the 
electric system of the heart and the preset time interval, 
the emptying of LA can be detected directly from analy-
sis of the LA ANGV signal (Fig. 6, middle panel, between 
lines 4 and 5). Using the LA ANGV signal as an indicator 
of LA emptying obviates the need to determine a fixed 
time interval. In a similar fashion, inter-ventricular delay 
may also be determined from systolic mechanical events, 
specifically LV ANGV signals recorded from RVa and CS. 
It must be emphasized that the above reasoning regard-
ing CRT is merely speculative and further studies are 
required to validate this hypothesis. Detecting myocar-
dial ischemia was not a goal of this work.
A significant limitation of this study was the small 
number of animals studied, restricting our conclusions 
to a level of trends. Nevertheless, we showed detect-
able physiological signals of mechanical movement of 
the heart that was reproducible and showed a tendency 
that reflects a novel and unique real-time record of heart 
movements. The ANGV and ACC signals studied were 
composite signals that characterize the amplitude and 
not the direction of motion. Signals occurred reproduc-
ibly relative to hemodynamic signals, ECG and tD, but 
they differed from animal to animal. For a given ani-
mal, signals remained the same throughout the study. 
In addition, the indices used to characterize STOS and 
ANGV signals, namely peak-to-peak STOS and peak 
ANGV, were insensitive to minor deflections of the sig-
nals. Rotation signals recorded with this experimental 
system should be validated using “gold standard” sys-
tems as speckle tracking echocardiography or MRI. 
Signals recorded from humans may differ, and must be 
characterized at baseline to enable assessment of the 
effects of physiology and pathology. Using our measur-
ing strategy, signals were sufficiently reproducible and 
reliable for real-time analysis. Many issues associated 
with the technology remain to be studied such as calcu-
lating the exact direction of motion, differentiating car-
diac motion from respiration and whole body motion, 
understanding regional motion abnormalities among 
others.
The volume overloading protocol was too mild to exert 
a detectable effect on the cardiac muscle. On the other 
hand, the effect of epinephrine administration was pos-
sibly too intense, as differences between RVa and CS 
leads were attenuated even with the lower epinephrine 
concentration.
In conclusion, the system presented provides novel 
real-time continuous physiologic information related to 
systolic and diastolic mechanical events. This informa-
tion may be used to study and possibly improve the effec-
tiveness of various therapies such as CRT; however, much 
research, development and validations are required.
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Appendix
Accelerometer and gyroscope in micro‑electro‑mechanical 
systems (MEMS)
In principle, accelerometers are composed of two com-
ponents: a casing upon which force operates causing it 
to move, and within the casing a mass component con-
nected to the casing for example by springs. When force 
is applied to the casing it accelerates; the mass within the 
casing is displaced to the point that the spring is able to 
accelerate the mass at the same rate as the casing. The 
displacement is calibrated and measured to give the mag-
nitude of acceleration. MEMS technology miniaturized 
the above principle to a microscopic level.
A mechanical gyroscope, in principle, is composed of 
a set of three gimbals allowing a rotor mounted on the 
inner most gimbal to revolve and continuously conserve 
the angular momentum. It is possible to measure the 
rotation of the outer two gimbals relative to the inner 
one, thereby measuring rotation. On the microscopic 
level (MEMS), the rotor is replaced by a vibrating ele-
ment using various technologies.
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